North America Cancer Tissue Diagnostics Market Trends and Analysis by 2027

Historic Data: 2016-2017 | Base Year: 2018 | Forecast Period: 2019-2027

North America Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type (Immunohistochemical Tests and In Situ Hybridization Tests) and Country

Report Date : Aug 2019
Report Code : TIPRE00006459

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 132

Page Updated: Feb 2025

Analysis Strategic Insights Market Drivers Regional Insights Report Scope Recent Developments FAQs

The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027.

The growth of the market is driven by the factors such as, growing cancer prevalence in North American region and new product launches & FDA approvals. However, the market is likely to slower down its growth due to the lack of reimbursement policies for cancer diagnosis in the region.

Frequent FDA approvals and product launches fuel the growth of the market for cancer tissue diagnostics. Most of the major market players are involved in the manufacturing wide range of cancer diagnostics products that offer maximum advantages and early diagnosis. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Furthermore, In March 2018, Agilent Technologies Inc. launched a new color for immunohistochemistry: HRP Magenta for Dako Omnis. The latest staining characteristics of the chromogen will help it for the assessment of skin and lung tissue. Thus, the constant developments in technology in diagnostics along with, FDA approvals accelerate the market growth during the forecast period.

US is expected to lead the market in the North America region owing to increasing prevalence of cancer, improved diagnosis and treatment of the condition along with the advancements made by market players. Moreover, the country has several hospitals, super specialty hospitals which offers diagnostic and treatment services for the cardiovascular diseases. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.

TIPRE00006459-img1

This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

NORTH AMERICA CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

Immunohistochemical Tests
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
In Situ Hybridization Tests
- Breast Cancer
- Lung Cancer
- Bladder Cancer
- Others

Company Profiles

F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Bio Rad Laboratories Inc.
Abbott
Enzo Life Sciences, Inc.
Agilent Technologies, Inc.
Cancer Genetics Inc.
Merck KGaA (Sigma-Aldrich Co. LLC)
Danaher Corporation
Abcam plc

North America Cancer Tissue Diagnostics Report Scope

Report Attribute	Details
Market size in 2018	US$ 923.79 Million
Market Size by 2027	US$ 1,587.38 Million
Global CAGR (2019 - 2027)	6.5%
Historical Data	2016-2017
Forecast period	2019-2027
Segments Covered	By Test Type Immunohistochemical Tests and In Situ Hybridization Tests
Regions and Countries Covered	North America US Canada Mexico
Market leaders and key company profiles	F. Hoffmann-La Roche Ltd Thermo Fisher Scientific Inc. Bio Rad Laboratories Inc. Abbott Enzo Life Sciences, Inc. Agilent Technologies, Inc. Cancer Genetics Inc. Merck KGaA (Sigma-Aldrich Co. LLC) Danaher Corporation

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the North America Cancer Tissue Diagnostics Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Global, Regional, Country
Industry and Competitive Landscape
Excel Dataset

Recent Reports

Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

Jean-Herve Jenn Chairman, Future Analytica

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

John Suzuki President and Chief Executive Officer, Board Director, BK Technologies

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

Ran Kedem Partner, Reali Technologies LTDs

Reason to Buy